Nuwellis signs co-promotion deal with Atrility for AtriAmp device
Nuwellis, the Nasdaq-listed cardiorenal medtech company, has entered a co-promotion and distribution agreement with Madison-based Atrility Medical for the AtriAmp device, a bedside tool designed to deliver continuous atrial electrograms in postoperative cardiac patients. The staged deal gives Nuwellis a low-capital route to broaden its critical care portfolio while leveraging its existing hospital relationships in paediatric and adult intensive care.
Under the initial phase, the two companies will run a six-month co-promotion programme spanning three Nuwellis sales territories across roughly nine Western and five Southeastern US states. Nuwellis will earn commissions on sales to both new and existing accounts in the covered regions. If the pilot meets expectations, Nuwellis is expected to convert to Atrility's exclusive US distributor for much of the country, taking on direct product purchasing, sales, and fulfilment responsibilities.
The device and its clinical case
AtriAmp is an FDA-cleared, single-patient-use sterile device intended for patients who have temporary epicardial pacing wires placed during cardiac surgery. It connects those wires to standard bedside ECG monitoring and external pacemaker equipment, providing a continuous, real-time atrial electrogram alongside support for temporary atrial pacing. The device is cleared for both adult and paediatric use, a characteristic Nuwellis regards as directly complementary to its existing focus on children's hospitals and critical care units.
A 2024 peer-reviewed qualitative study assessing early adoption of AtriAmp following congenital heart surgery gathered perspectives from 14 healthcare providers. Recurring themes included perceived reductions in time to arrhythmia diagnosis and treatment, more accurate rhythm identification, and improved clinician familiarity with atrial monitoring. The study's qualitative design means broad efficacy conclusions should be drawn cautiously, though the findings are consistent with the plausible workflow benefits the device is positioned to deliver.
Atrility chief executive Sean McCormick said the collaboration would "accelerate adoption and further establish AtriAmp as a standard component of postoperative cardiac rhythm management." Nuwellis president and CEO Mike McCormick described the arrangement as a "capital-efficient" way to expand product offerings without material incremental infrastructure cost.
Market context and competitive positioning
The postoperative cardiac monitoring segment sits at the intersection of cardiac surgery, critical care nursing, and cardiac electrophysiology workflows, a space where adoption of bedside adjuncts has historically been driven by clinician familiarity rather than formal procurement cycles. Nuwellis' established footprint in paediatric critical care, built around its ultrafiltration platform, gives it genuine access to the cardiac surgery teams and intensivists who are AtriAmp's primary users, a distribution advantage that a de novo commercial effort would be slow to replicate.
More broadly, the agreement reflects a pattern seen across small-cap medtech: companies with underutilised commercial capacity using distribution agreements to improve revenue per territory without proportionate cost growth. The staged structure, beginning with a defined pilot before committing to exclusivity, is a relatively conservative deal architecture and limits downside exposure for Nuwellis should uptake disappoint.
The critical care device market continues to attract interest from both strategic acquirers and specialist distributors, with device companies increasingly competing on commercial reach as much as on product differentiation. For Nuwellis, the next indicators to watch are pilot conversion rates across the initial territories and any announcement of an expanded geographic scope or formal exclusive distribution transition.